Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | CCR9 | P51686 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12251344 | 0.96 | CYP1A2 (0.57) | CYP2A6CYP1A2HSD17B1HSD17B2MAPT | |
| SCHEMBL24243100 | 0.83 | PTGS1 (0.45) | CYP2A6CYP1A2MAPTKDM4ELMNA | |
| SCHEMBL1782247 | 0.83 | CYP2A6 (0.52) | CYP2A6CYP1A2HSD17B1HSD17B2KDM4E | |
| SCHEMBL9420901 | 0.83 | CYP1A2 (0.52) | CYP2A6CYP1A2HSD17B1HSD17B2KDM4E | |
| SCHEMBL30010382 | 0.83 | ALDH1A1 (0.52) | CYP1A2MAPTALDH1A1LMNAALOX15 | |
| SCHEMBL348347 | 0.83 | ALDH1A1 (0.52) | CYP1A2MAPTALDH1A1LMNAALOX15 | |
| SCHEMBL28105147 | 0.81 | ALDH1A1 (0.50) | CYP1A2MAPTALDH1A1LMNAALOX15 | |
| SCHEMBL15413859 | 0.81 | CYP1A2 (0.54) | CYP2A6CYP1A2HSD17B1HSD17B2MAPT | |
| SCHEMBL18287957 | 0.81 | CYP2A6 (0.54) | CYP2A6CYP1A2HSD17B1HSD17B2KDM4E | |
| SCHEMBL13335867 | 0.81 | CYP3A4 (0.50) | ALDH1A1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230255950-A1 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | GEORGIA TECH RESEARCH CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230255950-A1 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | GEORGIA TECH RESEARCH CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230172911-A1 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-08 | — | — | US | disclosed |
| US-20230172911-A1 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-08 | — | — | US | disclosed |
| US-20230165811-A1 | METHOD FOR TREATING SYMPTOMS OF VIRAL INFECTIONS | WAINER IRVING W (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230165811-A1 | METHOD FOR TREATING SYMPTOMS OF VIRAL INFECTIONS | WAINER IRVING W (US) | 2023-06-01 | — | — | US | disclosed |
| US-11654137-B2 | 3-(hydroxy)-pyridin-4(1H)-one compounds and methods of making and using the same | GEORGIA TECH RESEARCH CORPORATION (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654137-B2 | 3-(hydroxy)-pyridin-4(1H)-one compounds and methods of making and using the same | GEORGIA TECH RESEARCH CORPORATION (US) | 2023-05-23 | — | — | US | disclosed |
| US-5670512-A | SKIN DISORDERS; REDUCTASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| US-5541190-A | TREATING BENIGN PROSTATIC HYPERPLASIA, MALE PATTERN BALDNESS, PROSTATIC CANCER, ANDROGENIC ALOPECIA | ELI LILLY AND COMPANY (US) | 1996-07-30 | — | — | US | disclosed |
| US-5495021-A | STEROID 5 ALPHA-REDUCTASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-27 | — | — | US | disclosed |
| US-5334767-A | Steroid 5a-reductase inhibitor | ELI LILLY AND COMPANY (US) | 1994-08-02 | — | — | US | disclosed |
| EP-0591583-A1 | Benzo (f) quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1994-04-13 | — | — | EP | disclosed |
| EP-0591582-A1 | Hexahydrobenzo (f) quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1994-04-13 | — | — | EP | disclosed |
| US-5250539-A | 5-alpha reductase inhibitors; administer as therapy for benign prostatic hyperplasia, hirsutism and acne | ELI LILLY AND COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
| US-5239075-A | PROCESS FOR THE PREPARATION OF BENZO (F) QUINOLINONES | ELI LILLY AND COMPANY (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0532190-A2 | Benzo f quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0531026-A1 | Hexahydrobenzo[f]quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1993-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11654137-B2 | 3-(hydroxy)-pyridin-4(1H)-one compounds and methods of making and using the same | KDM1B, KDM3A, KDM1A | CYP2A6 2718/4885CYP1A2 2929/4885HSD17B1 2324/4885 |
| US-20230255950-A1 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | KDM1B, KDM3A, KDM1A | CYP2A6 2718/4885CYP1A2 2929/4885HSD17B1 2324/4885 |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP2A6 4169/4885CYP1A2 3955/4885HSD17B1 4213/4885 |
| US-20230172911-A1 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | RRM2, RRM2B, RRM1 | CYP2A6 3973/4885CYP1A2 2663/4885HSD17B1 421/4885 |
| US-20230165811-A1 | METHOD FOR TREATING SYMPTOMS OF VIRAL INFECTIONS | ACE, CCL11, CRH | CYP2A6 1077/4885CYP1A2 1058/4885HSD17B1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.